Biopharma industry representatives are taking issue with some of the FDA’s more political proposals in the next round of user fee agreements, particularly ones that would limit the small business waiver to only US applicants …
Wave’s stock wavers on obesity drug data
Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don’t seem to agree.

